Reply to: “FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies,” “Conversion Chemotherapy for Locally Advanced Pancreatic Carcinoma: FOLFIRINOX or Gemcitabine?,” and “Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN”

M Michel Ducreux (Michel Ducreux, MD, PhD, Université Paris-Saclay 11Gustave Roussy Cancer Center, Tumor Cells Dynamics, INSERM, Villejuif, France; Matthieu Texier, MD, PhD, Biostatistics, Gustave Roussy Institut de Cancérologie, Villejuif, France; and Olivier Bouche, MD, PhD, Digestive Oncology Department, CHU Reims, Reims, France) M Matthieu Texier O Olivier Bouche

Article Details

Volume / Issue Vol. 44, Issue 2
Published January 10, 2026
Pages 132-133
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (3)

M

Michel Ducreux

Michel Ducreux, MD, PhD, Université Paris-Saclay 11Gustave Roussy Cancer Center, Tumor Cells Dynamics, INSERM, Villejuif, France; Matthieu Texier, MD, PhD, Biostatistics, Gustave Roussy Institut de Cancérologie, Villejuif, France; and Olivier Bouche, MD, PhD, Digestive Oncology Department, CHU Reims, Reims, France

M

Matthieu Texier

O

Olivier Bouche